Grifols blood typing products cover the main demands of immunohematology laboratories, offering optimized technology for various testing needs and the expert support of a specialized global partner so that patients receive safer transfusions, right on time.
DG Gel system
Discover how the DG Gel system is continuously growing by offering increased adaptability and making daily work easier. With scalable systems that adapt to laboratories' different throughput and capacities while using the same reagents and equivalent software, users can select the solution that is best suited for their typing needs.
- Designed to adapt to different workflow needs
- Developed to provide intuitive operation in a compact footprint
A new perspective on conventional antisera: Whether utilizing conventional reagents for all of your testing needs or using antisera for resolving problematic cases, it is important to have a wide range of conventional reagents to meet your needs.
Grifols now offers a wide range of monoclonal ABO and Rh antisera, monoclonal rare antisera for extended phenotyping, anti-human globulin, internal quality controls and enhancement media.
The new Erytra Eflexis2: Adaptability that fits your lab
Introducing the new Erytra Eflexis – the natural evolution in Grifols scalable, blood typing solutions. This truly flexible system allows laboratories to select the solution that is best suited to different workflow needs and capacities.
The Erytra and Erytra Eflexis are true scalable systems that offer different throughput and capacities, while using the same reagents and sharing the equivalent software suite. Therefore you can select the solution that is best suited for your laboratory.
| || || || |
| Erytra system || Erytra Eflexis system || Wadiana System || DG Reader |
ID CORE XT3
The new ID CORE XT kit, part of the BLOODchip platform, provides extended blood group genotyping to support improved patient care.
- Do more to prevent alloimmunization, even in your frequently transfused patients
- Enhanced transfusion compatibility in patients with complex antibody profiles
- Reduce the workload involved in complex antibody workups
- Develop a more information-rich rare donor database to provide better-matched blood to the patients who need it most.
1 Grifols Diagnostic Solutions, Inc. Data on file. June 2018
2 The Erytra Eflexis analyzer is CE marked in accordance with the Directive EC of the European Parliament and of the Council of October on in vitro diagnostic medical devices. This product is not available for commercial sale in the United States. It is intended for healthcare professionals only. Product registration and availability vary by country. To know whether the Erytra Eflexis system is available for sale in your country, please contact your local Grifols representative.
3ID CORE XT complies with the Directive 98/79/EC of the European Parliament and of the Council on in vitro diagnostic medical devices. CE mark certification. And, is sold in the US as IVD (FDA).
This information is intended for physicians and healthcare professionals only.
Product registration and availability vary by country. For more information on product availability, please contact us here.
Grifols Immunohematology Center & Clinical Laboratory
Grifols Immunohematology Center
Deliver improved patient care and enhance the efficiency of your laboratory with extended testing capabilities. Our CAP certified laboratory at the Grifols Immunohematology Center provides testing and support for the most challenging cases, saving you time and resources that would otherwise be consumed by complex workups.
The Grifols Immunohematology Center gives you the tools to:
- Improve patient outcomes by providing better matched blood faster
- Reduce costs and enhance efficiency in the blood bank and at the bedside
- Strengthen your expertise with our advanced consulting and continuing education opportunities
Grifols Clinical Laboratory
Our lab offers specialized testing panels for selected medical needs like therapeutic drug monitoring and diagnosis of different genetic diseases like familial hypercholesterolemia (FH).
TDMonitor is a new panel of assays to measure levels of Infliximab (Remicade, Inflectra, Remsima), Adalimumab (Humira) or Vedolizumab (Entyvio) and the anti-drug antibodies. Test results support clinicians, hospitals, and laboratories, globally, in making therapeutic decisions, improving patient therapy strategy and reducing the risk of debilitating disease progression. TDMonitor assays were developed and validated by Grifols CLIA-certified Clinical Laboratory in San Marcos, Texas. Samples may be mailed to the Texas laboratory. Following testing of the sample, a complete report, that includes recommendations with references, is generated and then submitted to the health care provider in 5-7 days.
Grifols offers genetic tests to diagnose familial hypercholesterolemia (FH) by using the advanced sequencing technologies. FH is a condition present in 1 in 250 people worldwide. This genetic condition causes lifelong levels of high cholesterol, which can lead to early coronary artery disease.